2022
Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co‐infection
Lodi S, Klein M, Rauch A, Epstein R, Wittkop L, Logan R, Rentsch C, Justice A, Touloumi G, Berenguer J, Jarrin I, Egger M, Puoti M, Monforte A, Gill J, Ceron D, van Sighem A, Linas B, van der Valk M, Hernán M, Collaboration H. Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co‐infection. Journal Of The International AIDS Society 2022, 25: e26048. PMID: 36562643, PMCID: PMC9784654, DOI: 10.1002/jia2.26048.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiviral AgentsCoinfectionFemaleHepacivirusHepatitis CHepatitis C, ChronicHIV InfectionsHumansMaleMiddle AgedRNATreatment OutcomeConceptsSustained virological responseHCV RNA testingDAA treatmentSVR ratesVirological responseProbability of SVRHepatitis C virus (HCV) cureRoutine HCV RNA testingActing antiviral (DAA) treatmentDAA treatment initiationCD4 cell countDirect antiviral agentsPresence of cirrhosisHCV RNA testEnd of treatmentClinical strataDAA recipientsHIV-HCVSVR assessmentSVR statusHIV acquisitionClinical characteristicsAntiviral treatmentTreatment initiationHCV genotypes
2021
Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015
Sun J, Althoff KN, Jing Y, Horberg MA, Buchacz K, Gill MJ, Justice AC, Rabkin CS, Goedert JJ, Sigel K, Cachay E, Park L, Lim JK, Kim HN, Re V, Moore R, Sterling T, Peters MG, Achenbach CJ, Silverberg M, Thorne JE, Mayor AM, Crane HM, Kitahata MM, Klein M, Kirk GD. Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015. JAMA Network Open 2021, 4: e2037512. PMID: 33595662, PMCID: PMC7890526, DOI: 10.1001/jamanetworkopen.2020.37512.Peer-Reviewed Original ResearchConceptsHCC incidence ratesHigher HCC riskHepatitis C virusHepatitis B virusModern cART eraCD4 cell countIncidence rateCART eraHCC riskHepatocellular carcinomaCohort studyTriple infectionNorth American AIDS Cohort CollaborationCell countAvailable CD4 cell countHigher HIV RNA levelsLow CD4 cell countsCombination antiretroviral therapy eraDiagnosis of HCCAnti-HCV seropositivityAntiretroviral therapy eraHBV-HCV coinfectionRecent HIV RNAHIV RNA levelsHBV e antigen
2020
Safety of Gabapentin Prescribed for Any Indication in a Large Clinical Cohort of 571,718 US Veterans with and without Alcohol Use Disorder
Rentsch CT, Morford KL, Fiellin DA, Bryant KJ, Justice AC, Tate JP. Safety of Gabapentin Prescribed for Any Indication in a Large Clinical Cohort of 571,718 US Veterans with and without Alcohol Use Disorder. Alcohol Clinical And Experimental Research 2020, 44: 1807-1815. PMID: 32628784, PMCID: PMC7540277, DOI: 10.1111/acer.14408.Peer-Reviewed Original ResearchConceptsAlcohol use disorderMental statusRelative riskGabapentin exposureUse disordersICD-9 diagnostic codesAdverse neurologic effectsPotential medication interactionsAltered mental statusIncidence of fallsClear dose-response relationshipLarge clinical cohortDose-response relationshipRace/ethnicityUnexposed patientsHepatitis CAdverse eventsMedication interactionsExcess riskNeurologic effectsUS veteransDiagnostic codesIncidence rateClinical cohortHigh riskExcess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals
Do A, Esserman DA, Krishnan S, Lim JK, Taddei TH, Hauser RG, Tate JP, Re VL, Justice AC. Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals. Journal Of General Internal Medicine 2020, 35: 2025-2034. PMID: 32342483, PMCID: PMC7352003, DOI: 10.1007/s11606-020-05782-6.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsHepacivirusHepatitis CHepatitis C, ChronicHumansProspective StudiesTreatment OutcomeWeight GainConceptsDAA treatmentExcess weight gainTreatment initiationWeight gainChronic hepatitis C virus (HCV) infectionHigh FIB-4 scoreHepatitis C virus infectionC virus infectionFIB-4 scoreHepatitis C infectionDirect acting antiviralsLiver disease progressionMultiple logistic regressionConclusionWeight gainDAA therapySVR achievementC infectionBaseline weightProspective studyExcess weightDisease progressionVirus infectionHigh riskPatientsBirth cohort
2018
Provider verification of electronic health record receipt and nonreceipt of direct-acting antivirals for the treatment of hepatitis C virus infection
Rentsch CT, Cartwright EJ, Gandhi NR, Brown ST, Rodriguez-Barradas MC, Goetz MB, Marconi VC, Gibert CL, Re VL, Fiellin DA, Justice AC, Tate JP. Provider verification of electronic health record receipt and nonreceipt of direct-acting antivirals for the treatment of hepatitis C virus infection. Annals Of Epidemiology 2018, 28: 808-811. PMID: 30195616, PMCID: PMC6318448, DOI: 10.1016/j.annepidem.2018.08.007.Peer-Reviewed Original ResearchConceptsHepatitis C virus infectionCorporate Data WarehouseChronic HCV infectionC virus infectionPositive predictive valuePredictive valueHCV infectionHCV treatmentVirus infectionVeterans Health Administration Corporate Data WarehouseChronic hepatitis C virus (HCV) infectionStudy periodModern treatment eraRetrospective cohort studyElectronic health record dataPharmacy fill recordsHealth record dataNegative predictive valueElectronic health recordsAntiviral regimenHCV therapyTreatment eraChart reviewCohort studyAntiviral treatment
2017
Risk of Acute Liver Injury After Statin Initiation by Human Immunodeficiency Virus and Chronic Hepatitis C Virus Infection Status
Byrne DD, Tate JP, Forde KA, Lim JK, Goetz MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Bedimo R, Freiberg MS, Justice AC, Kostman JR, Roy JA, Re V. Risk of Acute Liver Injury After Statin Initiation by Human Immunodeficiency Virus and Chronic Hepatitis C Virus Infection Status. Clinical Infectious Diseases 2017, 65: 1542-1550. PMID: 29020184, PMCID: PMC5850026, DOI: 10.1093/cid/cix564.Peer-Reviewed Original ResearchConceptsSevere acute liver injuryAcute liver injuryHuman immunodeficiency virusStatin initiatorsLower riskHCV statusCohort studyHazard ratioStatin nonusersLiver injuryUninfected personsImmunodeficiency virusChronic hepatitis C virus (HCV) infectionHepatitis C virus (HCV) infection statusHIV/HCV-coinfected patientsPropensity score-adjusted hazard ratiosHIV/HCV statusHepatitis C virus infectionVeterans Aging Cohort StudyC virus infectionAging Cohort StudyConfidence intervalsVirus infection statusDevelopment of liverAminotransferase elevationRisk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection
Re V, Zeldow B, Kallan MJ, Tate JP, Carbonari DM, Hennessy S, Kostman JR, Lim JK, Goetz MB, Gross R, Justice AC, Roy JA. Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection. Pharmacoepidemiology And Drug Safety 2017, 26: 1172-1181. PMID: 28722244, PMCID: PMC5624832, DOI: 10.1002/pds.4258.Peer-Reviewed Original ResearchConceptsHepatitis C virusHIV/HCV patientsHuman immunodeficiency virusHepatic decompensationAntiretroviral therapyHCV patientsCohort studyHazard ratioHIV/hepatitis C virus (HCV) coinfectionChronic hepatitis C virusHepatitis C virus coinfectionHIV/HCV coinfectionHIV-/HCV-coinfected patientsVeterans Aging Cohort StudyC virus coinfectionChronic hepatic injuryAging Cohort StudyRisk of deathToxic nucleoside analoguesMarginal structural modelsHCV coinfectionLiver decompensationART regimensDecompensation eventsHepatic injury
2016
HIV, Aging, and Viral Coinfections: Taking the Long View
Taddei TH, Re V, Justice AC. HIV, Aging, and Viral Coinfections: Taking the Long View. Current HIV/AIDS Reports 2016, 13: 269-278. PMID: 27614654, DOI: 10.1007/s11904-016-0327-7.Books
2015
Liver Fibrosis Progression in Hepatitis C Virus Infection After Seroconversion
Butt AA, Yan P, Re V, Rimland D, Goetz MB, Leaf D, Freiberg MS, Klein MB, Justice AC, Sherman KE. Liver Fibrosis Progression in Hepatitis C Virus Infection After Seroconversion. JAMA Internal Medicine 2015, 175: 178-185. PMID: 25485735, PMCID: PMC5017246, DOI: 10.1001/jamainternmed.2014.6502.Peer-Reviewed Original ResearchConceptsDiagnosis of cirrhosisLiver fibrosis progressionHepatic decompensation eventsDevelopment of cirrhosisFibrosis progressionHCV controlHepatic decompensationDecompensation eventsLiver fibrosisNegative HCV antibody test resultPositive HCV RNA test resultLower mean body mass indexHCV antibody test resultHCV RNA test resultsNational Veterans Affairs databaseHepatitis C virus infectionMean body mass indexHigher serum aminotransferase levelsHCV Infected VeteransRNA test resultsC virus infectionFIB-4 scoreFibrosis-4 indexSerum aminotransferase levelsMonths of follow
2014
Virologic response and haematologic toxicity of boceprevir‐ and telaprevir‐containing regimens in actual clinical settings
Butt AA, Yan P, Shaikh OS, Freiberg MS, Re V, Justice AC, Sherman KE, Team T. Virologic response and haematologic toxicity of boceprevir‐ and telaprevir‐containing regimens in actual clinical settings. Journal Of Viral Hepatitis 2014, 22: 691-700. PMID: 25524834, PMCID: PMC5020421, DOI: 10.1111/jvh.12375.Peer-Reviewed Original ResearchConceptsSustained virologic responsePEG/RBVHaematologic toxicityActual clinical settingsSVR ratesVirologic responseClinical settingHaematologic adverse eventsHCV Infected VeteransInterferon/ribavirinHCV genotype 1HCV RNA valuesPivotal clinical trialsHepatitis C virusBaseline cirrhosisHIV coinfectionPrimary endpointTreatment-naïveAdverse eventsC virusClinical trialsGenotype 1Genotype 1aSevere toxicityBoceprevirReply to Marcellin et al
Re V, Tate JP, Lim JK, Fiellin DA, Justice AC. Reply to Marcellin et al. Clinical Infectious Diseases 2014, 59: 1192-1193. PMID: 25015914, PMCID: PMC6276945, DOI: 10.1093/cid/ciu528.Peer-Reviewed Case Reports and Technical NotesHepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study.
Lo Re V, Kallan MJ, Tate JP, Localio AR, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Park L, Dubrow R, Reddy KR, Kostman JR, Strom BL, Justice AC. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Annals Of Internal Medicine 2014, 160: 369-79. PMID: 24723077, PMCID: PMC4254786, DOI: 10.7326/m13-1829.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Retroviral AgentsAscitesBacterial InfectionsCarcinoma, HepatocellularCoinfectionEsophageal and Gastric VaricesFemaleGastrointestinal HemorrhageHepatitis C, ChronicHIVHIV InfectionsHumansIncidenceLiver NeoplasmsMaleMedication AdherenceMiddle AgedPeritonitisRetrospective StudiesRNA, ViralTreatment OutcomeViral LoadConceptsCo-infected patientsHepatitis C virusHepatic decompensationAntiretroviral-treated patientsCohort studyNonblack raceC virusHepatitis C virus-monoinfected patientsChronic hepatitis C virusHigh rateAntiretroviral therapy eraDetectable HCV RNAIncident hepatic decompensationBaseline hemoglobin levelRetrospective cohort studySpontaneous bacterial peritonitisAdvanced hepatic fibrosisAdvanced liver fibrosisVeterans Health AdministrationDiagnosis of ascitesRate of decompensationTherapy eraHIV RNAVariceal hemorrhageHCV RNARelationship Between Alcohol Use Categories and Noninvasive Markers of Advanced Hepatic Fibrosis in HIV-Infected, Chronic Hepatitis C Virus–Infected, and Uninfected Patients
Lim JK, Tate JP, Fultz SL, Goulet JL, Conigliaro J, Bryant KJ, Gordon AJ, Gibert C, Rimland D, Goetz MB, Klein MB, Fiellin DA, Justice AC, Re V. Relationship Between Alcohol Use Categories and Noninvasive Markers of Advanced Hepatic Fibrosis in HIV-Infected, Chronic Hepatitis C Virus–Infected, and Uninfected Patients. Clinical Infectious Diseases 2014, 58: 1449-1458. PMID: 24569533, PMCID: PMC4001286, DOI: 10.1093/cid/ciu097.Peer-Reviewed Original ResearchConceptsChronic hepatitis C virusAdvanced hepatic fibrosisHuman immunodeficiency virusHepatitis C virusAlcohol use categoriesAlcohol-related diagnosesHIV/HCV-coinfected patientsHepatic fibrosisAlcohol consumptionNonhazardous drinkingBinge drinkingHIV/HCV groupAlcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaireVeterans Aging Cohort StudyFIB-4 indexAging Cohort StudyCross-sectional studyHCV groupHCV statusHIV-InfectedUninfected participantsChronic hepatitisUninfected patientsCohort studyLiver disease
2011
A Comparison of Treatment Eligibility for Hepatitis C Virus in HCV-Monoinfected Versus HCV/HIV-Coinfected Persons in Electronically Retrieved Cohort of HCV-Infected Veterans
Butt AA, McGinnis K, Skanderson M, Justice AC. A Comparison of Treatment Eligibility for Hepatitis C Virus in HCV-Monoinfected Versus HCV/HIV-Coinfected Persons in Electronically Retrieved Cohort of HCV-Infected Veterans. AIDS Research And Human Retroviruses 2011, 27: 973-979. PMID: 21338329, PMCID: PMC3719436, DOI: 10.1089/aid.2011.0004.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiviral AgentsElectronic Health RecordsEligibility DeterminationFemaleHepatitis C, ChronicHIV InfectionsHumansMaleMiddle AgedRegistriesVeteransConceptsChronic obstructive pulmonary diseaseHepatitis C virusDecompensated liver diseaseHCV-HIVTreatment eligibilityC virusCohort of HCVVA National Patient Care DatabaseNational Patient Care DatabasePharmacy Benefits Management databaseHCV treatment eligibilityHCV-HIV coinfectionRecent alcohol abuseHCV/HIVCurrent treatment guidelinesProportion of patientsObstructive pulmonary diseaseCoronary artery diseasePatient Care DatabaseActual clinical settingsCoinfected PersonsAggressive managementCommon contraindicationsPharmacy recordsRenal failure
2009
Hepatitis C treatment completion rates in routine clinical care
Butt AA, McGinnis KA, Skanderson M, Justice AC. Hepatitis C treatment completion rates in routine clinical care. Liver International 2009, 30: 240-250. PMID: 19889081, PMCID: PMC3132089, DOI: 10.1111/j.1478-3231.2009.02156.x.Peer-Reviewed Original ResearchConceptsPre-treatment anemiaTreatment completion ratesVA National Patient Care DatabaseHuman immunodeficiency virus (HIV) coinfectionNational Patient Care DatabasePharmacy Benefits Management databaseHepatitis C virus infectionCompletion ratesHigher comorbidity countC virus infectionImmunodeficiency virus coinfectionCoronary artery diseasePatient Care DatabaseRoutine clinical careClinical practice settingTreatment sitesInitiate therapyInterferon useComorbidity countPharmacy recordsStandard interferonArtery diseaseVirus coinfectionMultivariable analysisCare databaseHIV infection and the risk of diabetes mellitus
Butt AA, McGinnis K, Rodriguez-Barradas MC, Crystal S, Simberkoff M, Goetz MB, Leaf D, Justice AC. HIV infection and the risk of diabetes mellitus. AIDS 2009, 23: 1227-1234. PMID: 19444074, PMCID: PMC2752953, DOI: 10.1097/qad.0b013e32832bd7af.Peer-Reviewed Original ResearchConceptsRisk of diabetesHCV coinfectionHIV infectionUninfected veteransDiabetes mellitusRisk factorsVeterans Aging Cohort StudyMinority raceDiabetes mellitus differsPrevalent diabetes mellitusOdds of diabetesAging Cohort StudyCohort studyInhibitor therapyHIV statusUninfected personsLower BMIMale sexBaseline prevalenceARV treatmentOdds ratioHigh riskLow prevalenceHIVLower riskThe Association Between the Receipt of Lipid Lowering Therapy and HIV Status Among Veterans Who Met NCEP/ATP III Criteria for the Receipt of Lipid Lowering Medication
Freiberg MS, Leaf DA, Goulet JL, Goetz MB, Oursler KK, Gibert CL, Rodriguez-Barradas MC, Butt AA, Justice AC. The Association Between the Receipt of Lipid Lowering Therapy and HIV Status Among Veterans Who Met NCEP/ATP III Criteria for the Receipt of Lipid Lowering Medication. Journal Of General Internal Medicine 2009, 24: 334-340. PMID: 19127386, PMCID: PMC2642578, DOI: 10.1007/s11606-008-0891-7.Peer-Reviewed Original ResearchConceptsNCEP/ATP III criteriaATP III criteriaHIV viral loadViral loadAdult Treatment Panel guidelinesHigher HIV viral loadFive-site studyLipid lowering medicationsVeterans Aging CohortHIV infection statusLipid-Lowering TherapyProspective observational cohortCross-sectional analysisHIV-HCVLowering therapiesModifiable mediatorsObservational cohortResultsThe prevalenceHIV infectionHIV statusPharmacy dataCardiovascular diseasePanel guidelinesMAIN OUTCOMELow prevalence
2006
Rates and predictors of hepatitis C virus treatment in HCV–HIV‐coinfected subjects
BUTT AA, JUSTICE AC, SKANDERSON M, GOOD C, KWOH CK. Rates and predictors of hepatitis C virus treatment in HCV–HIV‐coinfected subjects. Alimentary Pharmacology & Therapeutics 2006, 24: 585-591. PMID: 16907891, DOI: 10.1111/j.1365-2036.2006.03020.x.Peer-Reviewed Original ResearchMeSH KeywordsCohort StudiesDelivery of Health CareFemaleHepatitis C, ChronicHIV InfectionsHumansMaleMiddle AgedConceptsHepatitis C virus (HCV) treatmentC virus treatmentHepatitis C virusHepatitis C virus-infected subjectsHCV-HIVVirus-infected subjectsC virusVirus treatmentTreatment ratesVeterans Affairs National Patient Care DatabaseDrug useNational Patient Care DatabaseImpact of comorbiditiesEffect of comorbidityPatient Care DatabaseICD-9 codesCoinfected subjectsHispanic racePharmacy dataBlack raceCare databaseMajor depressionPsychiatric illnessMild depressionBipolar disorder